secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-10-14T12:15:14+00:00
Accession:  0001683168-26-007834
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Valion Bio touts CDMO Velocity Bioworks as Section 232 tariffs hit imports up to 100%
--------------------------------------------------------------------------------

- Velocity Bioworks is Valion's wholly owned CDMO in San Antonio, offering process development, analytical services and early-phase GMP drug substance manufacturing.
- Microbial GMP manufacturing at scales up to 200 liters; GMP mammalian capabilities also maintained for biologics through early clinical development.
- New Section 232 pharmaceutical framework imposes tariffs of up to 100% on certain imported patented drugs and ingredients, effective September 29, 2026.
- Velocity supports Valion's lead candidate Entolimod, in development as a potential medical countermeasure for Acute Radiation Syndrome.
- Interim CEO Dean Zikria said Valion welcomes partner discussions; no new contracts, customers or financial impact were disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/0001683168-26-007834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007834/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer